Inspection Record

Integrative Pharmacy, LLC — FDA 483 Findings

US FDAInspected 2018-12-19Published 2019-04-30 3 findingsStability and storageLaboratory and QC controlsMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

2Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

3Material and supplier control

Each component is not tested for comformity with all appropriate written specification for purity st rength, and quality.

About this record

Extracted automatically from the document US FDA published on 2019-04-30. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Integrative Pharmacy, LLC company profile — full history US FDA documents, 2019 Go to Findings search